Core Scientific (CORZ) Current Deferred Revenue (2021 - 2026)

Core Scientific (CORZ) has 6 years of Current Deferred Revenue data on file, last reported at $654.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 974.76% year-over-year to $654.2 million; the trailing twelve-month figure through Mar 2026 stood at $654.2 million (up 974.76% YoY), and the FY2025 full-year result was $555.9 million, up 2965.24% from the prior year.
• Current Deferred Revenue rose to $654.2 million in Q1 2026, from $555.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $654.2 million in Q1 2026 to a low of $2.5 million in Q3 2025.
• A 5-year average of $123.8 million and a median of $71.8 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 93.23% in 2024 and jumped 2965.24% in 2025, its largest moves.
• Tracing CORZ's Current Deferred Revenue over 5 years: stood at $77.7 million in 2022, then tumbled by 87.35% to $9.8 million in 2023, then jumped by 84.48% to $18.1 million in 2024, then jumped by 2965.24% to $555.9 million in 2025, then increased by 17.7% to $654.2 million in 2026.
• Business Quant data shows CORZ's Current Deferred Revenue at $654.2 million in Q1 2026, $555.9 million in Q4 2025, and $2.5 million in Q3 2025.